Research programme: pain therapeutics - Galleon Pharmaceuticals

Drug Profile

Research programme: pain therapeutics - Galleon Pharmaceuticals

Alternative Names: GAL-044; GAL-044 IV; GAL-044 oral (PO)

Latest Information Update: 13 Oct 2014

Price : $50

At a glance

  • Originator Galleon Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Pain

Highest Development Phases

  • Preclinical Postoperative pain

Most Recent Events

  • 13 Oct 2014 Preclinical development is ongoing in USA
  • 09 May 2012 Research programme: pain therapeutics - Galleon Pharmaceuticals is available for licensing as of 09 May 2012. http://www.galleonpharma.com
  • 09 May 2012 Preclinical trials in Postoperative pain in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top